Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 13;12:90. doi: 10.1007/s40820-020-00428-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — In vivo biodistributions of Eu-FBCP/Cy5.5 (or Eu-s/Cy5.5) and antitumor immune responses from different treatments (1: PBS, 2: free PTX, 3: Eu-s/PTX, 4: Eu-FBCP/PTX, 5: aPL, 6: Eu-s/PTX + aPL, and 7: Eu-FBCP/PTX + aPL). a Calibration curves of fluorescent Cy5.5 in the concentration range of 1.5625 to 50.0000 µg/mL obtained using an animal imaging system after in vivo exposure. b Time profiles (0, 4, 8, 12, and 24 h) of the fluorescence to examine the tumor accumulation of Eu-FBCP/Cy5.5 and Eu-s/Cy5.5, as well as free Cy5.5 for comparison after intravenous injection. c Cy5.5 distributions in tumors for the time points. d, e Representative fluorescence images and the quantified data for major organs and tumors collected from the 24 h-treated mice. f Intratumoral maturation of the DCs from intravenous injections with different treatments (1–7) (n = 6; *p < 0.05, **p < 0.01, and ***p < 0.001). g Plots of CD4⁺–CD8⁺ T cells infiltrated into the tumor microenvironment after the treatments (1–7). h, i Plots of CD8⁺–granzyme B⁺ and CD8⁺–IFN-γ⁺ levels from intratumorally infiltrated CD8⁺ T cells after the treatments (1–7)